CFO
RAPT

Callan Family Office’s RAPT Therapeutics RAPT Stock Holding History

Callan Family Office’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,166
Closed -$109K – 938
2025
Q1 		$109K Buy
11,166
+3,911
+54% +$38.5K 0.01% 533
2024
Q4 		$91.7K Buy
+7,255
New +$92.2K 0.01% 618

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Callan Family Office's RAPT Position: Q2 2025 in Review

Callan Family Office sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 11,166 shares — an estimated $109K sold.

Callan Family Office first reported a position in RAPT in Q4 2024 and held it in 2 quarters. The position peaked at $109K in Q1 2025. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • Callan Family Office reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Callan Family Office sold 11,166 RAPT Therapeutics shares in Q2 2025, an estimated $109K.
  • Callan Family Office first reported a position in RAPT Therapeutics in Q4 2024 and held it in 2 quarters.
  • Callan Family Office's RAPT Therapeutics position peaked at $109K in Q1 2025.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Callan Family Office's 13F filing for Q2 2025, filed 24 Jul 2025.